Journal
FUTURE ONCOLOGY
Volume 18, Issue 20, Pages 2465-2473Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2022-0093
Keywords
chemotherapy; durvalumab; gastric cancer; gastroesophageal junction cancer; immune checkpoint inhibitors; immunotherapy; neoadjuvant-adjuvant; PD-L1; resectable
Categories
Funding
- AstraZeneca
Ask authors/readers for more resources
This study investigates the efficacy and safety of the immune checkpoint inhibitor durvalumab combined with FLOT chemotherapy in patients with resectable gastric/gastroesophageal junction cancer, and finds that the combination therapy improves clinical outcomes.
Standard-of-care for resectable gastric/gastroesophageal junction cancer includes surgery and neoadjuvant-adjuvant 5-fluorouracil-leucovorin-oxaliplatin-docetaxel (FLOT) chemotherapy. Early-phase clinical studies support further clinical development of the immune checkpoint inhibitor (ICI); durvalumab, an anti-PD-L1 antibody, in patients with gastric/gastroesophageal junction cancer. Accumulating evidence indicates that ICIs combined with FLOT chemotherapy improve clinical outcomes in patients with advanced or metastatic cancer. We describe the rationale for and the design of MATTERHORN, a randomized, double-blind, placebo-controlled, phase III study investigating the efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy followed by adjuvant durvalumab monotherapy in patients with resectable gastric/gastroesophageal junction cancer. The planned sample size is 900 patients, the primary end point is event-free survival and safety and tolerability will be evaluated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available